Advanced papillary renal cell carcinoma: Epidemiology, genomic drivers, current therapies, and ongoing trials

Siegel, 2022, Cancer statistics, 2022, CA Cancer J. Clin., 72, 7, 10.3322/caac.21708 Hsieh, 2017, Renal Cell Carcinoma, 3 Delahunt, 1997, Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors, Mod. Pathol., 10, 537 Saad, 2019, Trends in renal-cell carcinoma incidence and mortality in the United States in the last 2 decades: a SEER-based study, Clin Genitourin Cancer, 17, 10.1016/j.clgc.2018.10.002 Aron, 2008, Impact of gender in renal cell carcinoma: an analysis of the SEER database, Eur. Urol., 54, 133, 10.1016/j.eururo.2007.12.001 Lipworth, 2016, Renal cell cancer histological subtype distribution differs by race and sex, BJU Int., 117, 260, 10.1111/bju.12950 Qu, 2015, Age-dependent association between sex and renal cell carcinoma mortality: a population-based analysis, Sci. Rep., 5, 9160, 10.1038/srep09160 Sankin, 2011, Rate of renal cell carcinoma subtypes in different races, Int. Braz. J. Urol., 37, 29, 10.1590/S1677-55382011000100004 Wong, 2021, Racial diversity among histology of renal cell carcinoma at an urban medical center, Clin. Genitourin. Cancer, 19, e166, 10.1016/j.clgc.2020.12.010 Deng, 2019, A comparison of the prognosis of papillary and clear cell renal cell carcinoma: evidence from a meta-analysis, Medicine (Baltimore), 98, 10.1097/MD.0000000000016309 Wong, 2019, Morphologic subtyping as a prognostic predictor for survival in papillary renal cell carcinoma: type 1vs. type 2, Urol. Oncol., 37, 721, 10.1016/j.urolonc.2019.05.009 Chow, 2013, Racial disparity in renal cell carcinoma patient survival according to demographic and clinical characteristics, Cancer, 119, 388, 10.1002/cncr.27690 Srigley, 2013, The international society of urological pathology (ISUP) vancouver classification of renal neoplasia, Am. J. Surg. Pathol., 37, 1469, 10.1097/PAS.0b013e318299f2d1 Linehan, 2016, Comprehensive molecular characterization of papillary renal-cell carcinoma, N. Engl. J. Med., 374, 135, 10.1056/NEJMoa1505917 Pal, 2018, Characterization of clinical cases of advanced papillary renal cell carcinoma via comprehensive genomic profiling, Eur. Urol., 73, 71, 10.1016/j.eururo.2017.05.033 Sweeney, 2002, Biological significance of c-met over expression in papillary renal cell carcinoma, J. Urol., 168, 51, 10.1016/S0022-5347(05)64830-6 Marona, 2019, C-met as a key factor responsible for sustaining undifferentiated phenotype and therapy resistance in renal carcinomas, Cells, 8, 10.3390/cells8030272 Maher, 2018, Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management, World J. Urol., 36, 1891, 10.1007/s00345-018-2288-5 Schmidt, 1997, Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas, Nat. Genet., 16, 68, 10.1038/ng0597-68 Kovac, 2015, Nat. Commun., 6, 6336, 10.1038/ncomms7336 Yang, 2012, A novel fumarate hydratase-deficient HLRCC kidney cancer cell line, UOK268: a model of the Warburg effect in cancer, Cancer Genet., 205, 377, 10.1016/j.cancergen.2012.05.001 Menko, 2014, Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment, Fam. Cancer, 13, 637, 10.1007/s10689-014-9735-2 Motzer, 2002, Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology, J. Clin. Oncol, 20, 2376, 10.1200/JCO.2002.11.123 Ronnen, 2006, Treatment outcome for metastatic papillary renal cell carcinoma patients, Cancer, 107, 2617, 10.1002/cncr.22340 Vera-Badillo, 2015, Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis, Eur. Urol., 67, 740, 10.1016/j.eururo.2014.05.010 Connor Wells, 2017, Characterizing the outcomes of metastatic papillary renal cell carcinoma, Cancer Med., 6, 902, 10.1002/cam4.1048 Brown, 2022, Systematic review of treatment of metastatic non-clear cell renal cell carcinoma, Kidney Cancer, 6, 53, 10.3233/KCA-210005 Ravaud, 2015, First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French genitourinary group (GETUG)†, Ann. Oncol., 26, 1123, 10.1093/annonc/mdv149 Escudier, 2016, Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis, Eur. J. Cancer, 69, 226, 10.1016/j.ejca.2016.08.004 Tannir, 2016, Everolimus versus Sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial, Eur. Urol., 69, 866, 10.1016/j.eururo.2015.10.049 Armstrong, 2016, Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial, Lancet Oncol., 17, 378, 10.1016/S1470-2045(15)00515-X Hutson, 2021, A single-arm, multicenter, phase 2 study of Lenvatinib Plus Everolimus in patients with advanced non-clear cell renal cell carcinoma, Eur. Urol., 80, 162, 10.1016/j.eururo.2021.03.015 Srinivasan, 2020, Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer, J. Clin. Oncol., 38, 5004, 10.1200/JCO.2020.38.15_suppl.5004 Pal, 2021, A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial, Lancet, 397, 695, 10.1016/S0140-6736(21)00152-5 Leger, 2020, A phase II study of the selective MET kinase inhibitor INC280 in advanced papillary renal cell cancer, J. Clin. Oncol., 38, 5075, 10.1200/JCO.2020.38.15_suppl.5075 Choueiri, 2013, Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma, J. Clin. Oncol., 31, 181, 10.1200/JCO.2012.43.3383 Choueiri, 2020, Efficacy of Savolitinib vs Sunitinib in patients with MET-driven papillary renal cell carcinoma: the SAVOIR phase 3 randomized clinical trial, JAMA Oncol., 6, 1247, 10.1001/jamaoncol.2020.2218 Twardowski, 2017, Parallel (Randomized) phase II evaluation of Tivantinib (ARQ197) and Tivantinib in combination with Erlotinib in papillary renal cell carcinoma: SWOG S1107, Kidney Cancer, 1, 123, 10.3233/KCA-170018 Jang, 2021, Immunotherapies in Genitourinary Oncology: where are we now? Where are we going?, Cancers (Basel), 13, 10.3390/cancers13205065 Koshkin, 2018, Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma, J. Immunother Cancer, 6, 10.1186/s40425-018-0319-9 McKay, 2018, The clinical activity of PD-1/PD-L1 inhibitors in metastatic non-clear cell renal cell carcinoma, Cancer Immunol. Res., 6, 758, 10.1158/2326-6066.CIR-17-0475 Chahoud, 2020, Nivolumab for the treatment of patients with metastatic non-clear cell renal cell carcinoma (nccRCC): a single-institutional experience and literature meta-analysis, Oncologist, 25, 252, 10.1634/theoncologist.2019-0372 de Vries-Brilland, 2020, Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study, Eur. J. Cancer, 136, 76, 10.1016/j.ejca.2020.02.019 Barata, 2020, Outcomes with first-line PD-1/PD-L1 inhibitor monotherapy for metastatic renal cell carcinoma (mRCC): a multi-institutional cohort, Front. Oncol., 10, 10.3389/fonc.2020.581189 McDermott, 2021, Open-label, single-arm, phase II study of Pembrolizumab monotherapy as first-line therapy in patients with advanced non-clear cell renal cell carcinoma, J. Clin. Oncol., 39, 1029, 10.1200/JCO.20.02365 Gupta, 2020, Clinical activity of ipilimumab plus Nivolumab in patients with metastatic non-clear cell renal cell carcinoma, Clin. Genitourin Cancer, 18, 429, 10.1016/j.clgc.2019.11.012 Tachibana, 2021, Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma, Jpn. J. Clin. Oncol., 51, 646, 10.1093/jjco/hyaa229 McGregor, 2020, Results of a multicenter phase II study of Atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma with variant histology and/or Sarcomatoid features, J. Clin. Oncol., 38, 63, 10.1200/JCO.19.01882 Lee, 2022, Phase II trial of Cabozantinib plus Nivolumab in patients with non-clear-cell renal cell carcinoma and genomic correlates, J. Clin. Oncol., 40, 2333, 10.1200/JCO.21.01944 Pal, 2021, Cabozantinib in combination with atezolizumab for advanced renal cell carcinoma: results from the COSMIC-021 study, J. Clin. Oncol., 39, 3725, 10.1200/JCO.21.00939 Rodriguez, 2021, Clinical activity of durvalumab and savolitinib in MET-driven, metastatic papillary renal cancer, J. Clin. Oncol., 39, 4511, 10.1200/JCO.2021.39.15_suppl.4511